Phase 1 Study of VE800 and Nivolumab in Patients with Selected Types of Advanced or Metastatic Cancer
Brief description of study
To evaluate the safety and tolerability of VE800 in combination with nivolumab using Common Terminology Criteria for Adverse Events (CTCAE, v. 5.0). To evaluate clinical activity as measured by objective response rate (ORR) of the study drug combination using Response Evaluation Criteria in Solid Tumors (RECIST)
Clinical Study Identifier: s19-00845
ClinicalTrials.gov Identifier: NCT04208958
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
